Evidence map›Paper›PMID 39351317›Full record

ArticleAtherosclerosis plus2024

Eligibility for marine omega-3 fatty acid supplementation after acute coronary syndromes.

Cédric Follonier, Gabriel Rabassa, Mattia Branca, David Carballo, Konstantinos Koskinas, Dik Heg, David Nanchen, Lorenz Räber, Roland Klingenberg, Moa Lina Haller and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Atherosclerosis plus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Cédric FollonierFaculty of Medicine, University of Geneva, Switzerland.
Gabriel RabassaFaculty of Medicine, University of Geneva, Switzerland.
Mattia BrancaDepartment of Clinical Research, University of Bern, Switzerland.
David CarballoDivision of Cardiology, Geneva University Hospitals, Switzerland.
Konstantinos KoskinasDepartment of Cardiology, University Hospital of Bern, Switzerland.
Dik HegDepartment of Clinical Research, University of Bern, Switzerland.
David NanchenCenter for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.
Lorenz RäberDepartment of Cardiology, Bern University Hospital and University of Bern, Bern, Switzerland.
Roland KlingenbergDepartment of Cardiology, University Heart Center, University of Zurich, Switzerland.
Moa Lina HallerInstitute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
Sebastian CarballoDepartment of General Internal Medicine, Geneva University Hospitals, Geneva, Switzerland.
Stephan WindeckerDepartment of Cardiology, University Hospital of Bern, Switzerland.
Christian M MatterDepartment of Cardiology, University Heart Center, University of Zurich, Switzerland.
Nicolas RodondiInstitute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
François MachDivision of Cardiology, Geneva University Hospitals, Switzerland.
Baris GencerDivision of Cardiology, Geneva University Hospitals, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aims: The 2019 European Society of Cardiology guidelines for the management of dyslipidemia consider the use of high-dose marine omega-3 fatty acid (FA) eicosapentaenoic acid (EPA) supplementation (icosapent ethyl 2 × 2g/day) to lower residual cardiovascular risk in high-risk patients with hypertriglyceridemia. This study aimed to assess the eligibility for omega-3 FA-EPA supplementation in patients with acute coronary syndromes (ACS). Methods: In a prospective Swiss cohort of patients hospitalized for ACS, eligibility for marine omega-3 FA-EPA, defined as plasma triglyceride levels ranging from 1.5 to 5.6 mmol/l, was assessed at baseline and one-year follow-up and compared across subgroups. Lipid-lowering therapy intensification with statin and ezetimibe was modelled to simulate a hypothetical systematic treatment and its effect on omega-3 FA-EPA supplementation eligibility. Results: Of 2643 patients, 98 % were prescribed statin therapy at discharge, including 62 % at a high-intensity regimen; 93 % maintained it after one year, including 53 % at a high-intensity regimen. The use of ezetimibe was 3 % at discharge and 7 % at one year. Eligibility was observed in 32 % (32 % men, 29 % women) one year post-ACS. After modelling systematic treatment with statins, ezetimibe, and both, eligibility decreased to 31 %, 25 % and 24 %, respectively. Eligibility was higher in individuals aged <70 (34 vs 25 %), smokers (38 vs 28 %), diabetics (46 vs 29 %), hypertensive (35 vs 29 %), and obese patients (46 vs 22 % for normal weight), all with p-values <0.001. Conclusion: In a contemporary Swiss cohort of patients with ACS, up to 32 % would be eligible for omega-3 FA-EPA supplementation one year after ACS, highlighting an opportunity to mitigate residual cardiovascular risk in patients with ACS and hypertriglyceridemia.

Indexed as

Acute coronary syndromeDyslipidemiaHeart disease risk factorHypertriglyceridemiaOmega-3 fatty acidsSecondary prevention

Identifiers

PMID39351317
PMCPMC11439545

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.